Video Resource Library
-
ISET 2026: Dr. Parag Patel on Venous Applications of Computer Assisted Vacuum Thrombectomy (CAVT)
Dr. Patel’s presentation on Lightning Flash 3.0 and the Evolution of CAVT from ISET on Feb. 10, 2026.
Dr. Patel’s presentation on Lightning Flash 3.0 and the Evolution of CAVT from ISET on Feb. 10, 2026.
-
ISET 2026: Dr. Daniel Clair on Arterial Applications of Computer Assisted Vacuum Thrombectomy (CAVT)
Dr. Clair’s presentation on Lightning Bolt and the Evolution of CAVT from the International Symposium on Endovascular Therapy on Feb. 10, 2026.
Dr. Clair’s presentation on Lightning Bolt and the Evolution of CAVT from the International Symposium on Endovascular Therapy on Feb. 10, 2026.
-
RCT of Mechanical Thrombectomy with Anticoagulation vs. Anticoagulation Alone for Acute Intermediate-High Risk PE: Primary Outcome, Functional Endpoints, and Core Lab Findings from STORM-PE
Dr. Robert Lookstein, MD, MSc, co-global principal investigator of the STORM-PE randomized controlled trials and professor of radiology and surgery at the Icahn School of Medicine at Mount Sinai presents the primary outcomes, functional endpoints, and core lab findings of the STORM-PE RCT.
Dr. Robert Lookstein, MD, MSc, co-global principal investigator of the STORM-PE randomized controlled trials and professor of radiology and surgery at the Icahn School of Medicine at Mount Sinai presents the primary outcomes, functional endpoints, and core lab findings of the STORM-PE RCT.
-
Case Spotlight by Dr. Strickland
Poor Surgical Candidate: MMA Embolization with SwiftPAC in a Type III Arch.
Poor Surgical Candidate: MMA Embolization with SwiftPAC in a Type III Arch.
-
Dr. Rosovsky at VIVA 2025: Landmark STORM-PE RCT Indicates CAVT with Anticoagulation Significantly Improves Functional Outcomes for PE Patients
Dr. Rachel Rosovsky, MD, MPH, Co-Principal Global Investigator of STORM-PE RCT, discusses the secondary endpoints of the landmark STORM-PE RCT and what these foundational results mean for advancing PE treatment.
Dr. Rachel Rosovsky, MD, MPH, Co-Principal Global Investigator of STORM-PE RCT, discusses the secondary endpoints of the landmark STORM-PE RCT and what these foundational results mean for advancing PE treatment.
-
Dr. Clair and Dr. Genovese on CAVT for ALI Management Video
Dr. Dan Clair and Dr. Elizabeth Genovese share how using Penumbra’s CAVT system for Acute Limb Ischemia has helped improve their patients’ outcomes.
Dr. Dan Clair and Dr. Elizabeth Genovese share how using Penumbra’s CAVT system for Acute Limb Ischemia has helped improve their patients’ outcomes.
-
Dr. Lookstein at TCT 2025: Landmark STORM-PE RCT Finds Superior Efficacy with CAVT with Anticoagulation Compared to Anticoagulation Alone for PE Patients
Dr. Robert Lookstein, Co-Principal Global Investigator of the STORM-PE RCT, discusses the study’s primary endpoints and what these foundational results mean for advancing PE treatment.
Dr. Robert Lookstein, Co-Principal Global Investigator of the STORM-PE RCT, discusses the study’s primary endpoints and what these foundational results mean for advancing PE treatment.
-
Meet the Experts FPE30 with Dr. Charles Matouk
Dr. Charles Matouk, Chief of Neurovascular Surgery at Yale, examines how time influences the First Pass Effect (FPE) and introduces FPE30.
Dr. Charles Matouk, Chief of Neurovascular Surgery at Yale, examines how time influences the First Pass Effect (FPE) and introduces FPE30.